

1 **Genome-wide DNA methylation, imprinting, and gene expression in human placentas**  
2 **derived from Assisted Reproductive Technology**

3

4 Auvinen P<sup>\*1</sup>, Vehviläinen J<sup>\*1</sup>, Rämö K<sup>1</sup>, Laukkanen I<sup>1</sup>, Marjonen-Lindblad H<sup>1</sup>, Wallén E<sup>1</sup>,  
5 Söderström-Anttila V<sup>2</sup>, Kahila H<sup>3</sup>, Hydén-Granskog C<sup>3</sup>, Tuuri T<sup>3</sup>, Tiitinen A<sup>3</sup>, Kaminen-Ahola  
6 N<sup>1</sup>

7

8 **AFFILIATIONS**

9 *1. Environmental Epigenetics Laboratory, Department of Medical and Clinical Genetics,*  
10 *Medicum, University of Helsinki, Helsinki, Finland*

11 *2. The Family Federation of Finland, Fertility Clinic and University of Helsinki, Helsinki,*  
12 *Finland*

13 *3. Department of Obstetrics and Gynecology, Helsinki University Hospital and University of*  
14 *Helsinki, Helsinki, Finland*

15

16 Corresponding author:

17 Nina Kaminen-Ahola, [nina.kaminen@helsinki.fi](mailto:nina.kaminen@helsinki.fi)

18

19 \*Equal contribution

20

21 **ABSTRACT**

22

23 Assisted reproductive technology (ART) has been associated with increased risk for growth  
24 disturbance and imprinting disorders, but the molecular mechanisms and whether they are a  
25 result of the ART procedures or the underlying subfertility are unknown. Here we performed  
26 genome-wide DNA methylation analysis by EPIC Illumina microarrays and gene expression  
27 analysis by mRNA sequencing for a total of 80 ART and 77 control placentas, including  
28 separate procedure- and sex-specific analyses. ART-associated changes enriched in the  
29 pathways of hormonal regulation, insulin resistance, neuronal development, and  
30 vascularization. Observed changes in the number of stromal cells as well  
31 as *TRIM28* and *NOTCH3* expressions in ART placentas indicated impaired angiogenesis and  
32 growth. The enrichment of DNA methylation changes in the imprinted regions and alterations  
33 in *TRIM28*, *ZFP57*, and *NLRP5* suggested defective stabilization of the imprinting.

**NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

34 Furthermore, downregulated expression of imprinted endocrine signaling molecule *DLKI*,  
35 associated with both ART and subfertility, provides a potential mechanism for the metabolic  
36 and phenotypic features associated with ART.

37

## 38 INTRODUCTION

39

40 Approximately one in six couples experience infertility worldwide and the usage of Assisted  
41 Reproductive Technology (ART) has increased over the last decades. To date over ten million  
42 children have been conceived through these technologies<sup>1</sup>. The main procedure of ART is *in*  
43 *vitro* fertilization (IVF), which may also include intracytoplasmic sperm injection (ICSI), in  
44 which a single sperm cell is injected into the oocyte cytoplasm. In addition to the freshly  
45 transferred embryos (FRESH), also embryo cryopreservation and frozen embryo transfer  
46 (FET) can be a part of IVF or ICSI procedures. Less invasive *in vivo* fertility treatments, such  
47 as intrauterine insemination (IUI) and hormone treatments to induce ovulation, are also widely  
48 used.

49

50 Although children conceived by using the treatments are generally healthy, ART has been  
51 associated with increased risks for adverse obstetric and perinatal outcomes such as preterm  
52 birth (PTB), low birth weight (LBW), birth defects, and placental anomalies<sup>2,3</sup>.  
53 Additionally, long-term effects such as rapid postnatal growth, female early onset puberty as  
54 well as cardiovascular and metabolic disorders have been associated with the ART phenotype<sup>4</sup>  
55 <sup>6</sup>. An increased risk for certain imprinting disorders<sup>7,8</sup> and a tendency towards higher risk of  
56 neurodevelopmental disorders has furthermore been reported<sup>9</sup>. There are method-associated  
57 risks, and it has been reported that FRESH derived children have a higher risk for PTB, LBW,  
58 and for being small for gestational age (SGA) compared to natural conception. A higher risk  
59 of pre-eclampsia and a higher risk for being large for gestational age (LGA) has been noted in  
60 pregnancies after FET compared to FRESH<sup>10</sup>. However, it is unclear whether these  
61 associations are the result of ART technology *per se* or the underlying subfertility.

62

63 The mechanisms by which ART or infertility increases the risk for adverse outcomes are  
64 unknown. ART has been suggested to affect fetal development through epigenetic  
65 modifications as the procedures take place during extensive epigenetic reprogramming in the  
66 gametogenesis and early embryogenesis. Indeed, ART-associated DNA methylation (DNAm)  
67 profiles have been reported in several epigenome-wide association studies (EWASs) of human

68 blood<sup>11-18</sup> and placenta<sup>19-22</sup>. Increasing evidence suggest that the placenta is particularly  
69 susceptible to epigenetic changes caused by ART and/or infertility<sup>23-25</sup> and alterations have  
70 been found especially in imprinted genes<sup>19-22</sup> and also in epigenetically silenced repetitive  
71 elements (REs)<sup>26-28</sup>. However, the results of EWASs are not consistent, ART procedure-  
72 specific EWASs as well as genome-wide gene expression studies for placentas are scarce, and  
73 studies controlled for placental cell type heterogeneity are lacking.

74

75 Here, we explored ART-associated genome-wide DNAm by microarrays (Illumina's Infinium  
76 MethylationEPIC) and gene expression by 3'mRNA sequencing (mRNA-seq) of full-term  
77 placental samples from ART and naturally conceived singleton newborns (Table 1). The effect  
78 of cell type heterogeneity was excluded by adjusting the DNAm analyses by placental cell  
79 types. Furthermore, ART-associated phenotypic features were examined. The procedure-  
80 specific changes were investigated by analyzing the ART samples in subgroups: newborns  
81 derived from IVF or ICSI methods as well as from FRESH or FET procedures. Moreover, to  
82 separate the effects of decreased fertility from ART procedures on gene expression, we  
83 analyzed placental samples from pregnancies of couples who had went through IUI as well as  
84 from subfertile (SF) couples who were about to start or already started ART treatment but got  
85 pregnant spontaneously.

86

87 Males and female fetuses have been shown to differ in terms of placental DNAm<sup>29,30</sup> as well  
88 as in their ability to adapt to adverse intrauterine environments<sup>31,32</sup>. In the ART studies, it has  
89 been shown that males have a higher risk to be LGA compared to females<sup>33-35</sup>, but still only a  
90 few sex-specific EWASs have been performed so far<sup>12,18,22</sup>. In the current study, we performed  
91 sex-specific analyses by examining placentas of male and female newborns separately,  
92 including sex chromosomes.

93

## 94 **RESULTS**

95

### 96 **Participant characteristics and placental phenotypes**

97 General characteristics of 80 ART and 77 naturally conceived control newborns as well as their  
98 mothers were compared. All ART and subgroup-specific information of the phenotype analysis  
99 can be found in the Supplementary Table 1. In general, the phenotypes did not differ  
100 significantly between ART and control newborns. A total of five SGA (6.3%) (IVF male, two  
101 IVF females and two ICSI females, all FRESH) and five LGA (6.3%) (IVF-FRESH, ICSI-

102 FRESH, and ICSI-FET males as well as ICSI-FRESH and ICSI-FET females) newborns were  
103 in the ART group, and two SGA newborns (2.6%, male and female) in controls. The gestational  
104 age (GA) of ART newborns was significantly shorter, particularly in females (ART:  $n = 44$ ,  
105 control:  $n = 35$ ) ( $P = 0.003$ ,  $P = 0.004$ , respectively), and this was driven by IVF and FRESH  
106 newborns ( $n = 50$ ,  $n = 42$ , respectively). In the ART group, one (1.3%) IVF newborn was  
107 preterm (gestational week 36+5). According to the Finnish growth charts<sup>36</sup>, the head  
108 circumference (HC) SD (z-score) of ICSI female newborns was significantly smaller compared  
109 to control females ( $n = 18$ ,  $n = 35$ , respectively) ( $P = 0.018$ ). Furthermore, IUI and SF newborns  
110 as well as their mothers were compared ( $n = 12$ ,  $n = 11$ , respectively). The GA of SF newborns  
111 was significantly shorter compared to controls ( $P = 0.005$ ) and one female LGA newborn was  
112 observed in this group. The mothers of ART newborns were significantly older and they gained  
113 less weight during pregnancy compared to the mothers of control newborns ( $P < 0.0001$ ,  $P =$   
114  $0.002$ , respectively). Also, the mothers of IUI and SF newborns were significantly older, and  
115 the body mass index (BMI) of the IUI mothers was higher compared to controls ( $P = 0.016$ ,  $P$   
116  $= 0.017$ ,  $P = 0.006$ , respectively).

117  
118 When the placentas of ART and control newborns were compared, no significant difference in  
119 weights was observed (Supplementary Table 1). However, in ART subgroups, FET placentas  
120 were significantly heavier compared to FRESH ( $n = 38$ ,  $n = 50$ , respectively). The DNAm  
121 profiles of placental samples and cell type fragment analysis were utilized to determine  
122 potential differences between ART and control placentas in five major placental cell types:  
123 syncytiotrophoblasts, trophoblasts, stromal cells, Hofbauer cells, and endothelial cells  
124 (Supplementary Fig. 1). When comparing the fragments between ART ( $n = 80$ ) and control ( $n$   
125  $= 77$ ) samples, we observed significantly lower number of stromal cells in the ART placentas  
126 ( $P = 0.002$ ) (Supplementary Fig. 2) as well as ICSI and FRESH subgroup placentas compared  
127 to controls ( $n = 30$ ,  $n = 42$ ,  $n = 77$ , respectively) ( $P = 0.02$  and  $P = 0.03$ , respectively). Sex-  
128 specific analyses revealed significantly lower number of stromal cells in female ART, ICSI,  
129 and FRESH placentas compared to control females ( $n = 44$ ,  $n = 18$ ,  $n = 28$ ,  $n = 35$ , respectively)  
130 ( $P = 0.003$ ,  $P = 0.001$ ,  $P = 0.01$ , respectively) (Supplementary Fig. 2). Furthermore, to exclude  
131 the variation caused by different ART procedures, we compared FRESH and FET placentas  
132 derived only from the IVF to the controls. Significantly more endothelial cells were observed  
133 in the IVF-FRESH placentas compared to the IVF-FET placentas ( $n = 25$ ,  $n = 25$ , respectively)  
134 ( $P = 0.01$ ).



135

### 136 **ART-associated genome-wide DNAm in placenta**

137 To investigate genome-wide average DNAm level (GWAM) in the ART and control placentas  
138 ( $n = 80$ ,  $n = 77$ , respectively), we used the DNAm level of all 746,966 probes in the microarrays  
139 (general characteristics in Supplementary Table 1). Furthermore, we examined ART-  
140 associated DNAm in REs by comparing the predicted mean DNAm level of CpGs in Alu,  
141 endogenous retrovirus (EVR), and long interspersed nuclear element (LINE1) sequences in  
142 ART and control placentas. However, we did not observe significant ART-associated  
143 alterations in GWAM levels either overall or at any genomic locations relative to gene or CpG  
144 island, or in REs (Supplementary Fig. 3 and 4, respectively).

145

146 ART-associated genome-wide DNAm was explored by using linear regression model adjusted  
147 for cell type, sex, as well as maternal pre-pregnancy BMI and age as covariates. The analysis  
148 resulted in 6728 significantly differentially methylated CpG sites (3524 hypo- and 3204  
149 hypermethylated) with  $FDR < 0.05$  (Fig. 1a, Supplementary Table 2). To separate the most  
150 prominent changes and to minimize false positive hits, we focused on the CpG sites with  
151 DNAm difference of  $\geq 5\%$  between ART and control placentas, which are termed as  
152 differentially methylated positions (DMPs). There were 164 DMPs associating with 126 genes  
153 in ART placentas ( $FDR < 0.05$ ,  $\Delta\beta \leq -0.05$  and  $\Delta\beta \geq 0.05$ ), of which 99 were hypo- and 65  
154 hypermethylated. Further, we tested for differentially methylated regions (DMRs) defined as a  
155 region with maximal allowed genomic distance of 1000 bp containing three or more CpGs with  
156  $P < 0.05$  according to Fisher's combined probability test. A total of 787 DMRs associating with  
157 687 genes in ART placentas were revealed (Supplementary Table 3).

158

159 To get a comprehensive picture on the biological processes (BPs) in which ART-associated  
160 DMRs cluster, we performed pathway analyses (Supplementary Table 4). Gene ontology (GO)  
161 enrichment analysis of ART-associated DMRs revealed BPs involved in gliogenesis and  
162 hormone secretion ( $FDR < 0.05$ ), specifically insulin secretion ( $P < 0.05$ ). When only DMRs  
163 located in the regulatory regions (200 and 1500 bp from transcription starting sites (TTSs))  
164 were analyzed, also inflammatory response and cytokine production brought forth ( $P < 0.05$ ).  
165 According to KEGG enrichment analysis, ART-associated DMRs linked to terms such as  
166 insulin resistance, Type I and II diabetes mellitus (T1D and T2D), growth hormone synthesis,

167 secretion, and action, as well as GnRH secretion, estrogen signaling pathway, and TNF  
168 signaling pathway ( $P < 0.05$ ) (Fig. 1b).

169

170 Furthermore, placental DMRs in the current study associated with *CHRNE*, *DUSP22*,  
171 *NECAB3*, *RASL11B*, *SNCB*, and *FSCN2*, as well as both DMRs and DMPs with *PCDHGB4*,  
172 *APC2*, and *MSX1*, which all had DNAm changes in the same direction as in the blood samples  
173 of ART derived individuals in previous EWASs<sup>14,16,17</sup>. Moreover, *FDFT1*, *FGF5*, *MYO7A*,  
174 *TRIM72*, and *C4orf51* have also been observed in a previous study, in which ART placentas  
175 were compared to placentas from IUI and SF pregnancies<sup>21</sup>.

176

### 177 **ART-associated genome-wide gene expression in placenta**

178 To study genome-wide ART-associated gene expression, we performed mRNA-seq for ART  
179 and control placentas ( $n = 59$ ,  $n = 39$ , respectively) (general characteristics in Supplementary  
180 Table 5). When the mRNA-seq model was adjusted by sex, we observed 71 significantly  
181 differentially expressed genes (DEGs) (FDR  $< 0.05$ ) of which 53 were downregulated and 18  
182 upregulated (Fig. 1c, Supplementary Table 6). One of the most prominently downregulated  
183 gene was *delta like non-canonical Notch ligand 1 (DLK1)* (Fig. 1d). This paternally expressed  
184 imprinted gene is essential for embryonic development and growth, and its malfunction has  
185 been connected to metabolic abnormalities, such as obesity, T2D, and hyperlipidemia in  
186 previous human studies<sup>37</sup>. Other interesting downregulated DEGs were *tripartite motif-*  
187 *containing protein 28 (TRIM28)* and *notch receptor 3 (NOTCH3)* (Fig. 1d). *TRIM28* is a  
188 mediator of epigenetic modifications and its haplosufficiency in mice has been linked to  
189 testicular degeneration, age-dependent infertility<sup>38</sup>, and bi-stable epigenetic obesity<sup>39</sup>.  
190 Furthermore, *TRIM28* is essential in decidualization and implantation<sup>40</sup> and is involved in the  
191 regulation of female obesity<sup>41</sup>. *NOTCH3*, which is expressed mainly in vascular smooth muscle  
192 and pericytes, is needed for the development of fully functional arteries in mouse<sup>42</sup>, and  
193 recently it has been reported that *NOTCH3* signaling controls human trophoblast stem cell  
194 expansion and proliferation<sup>43</sup>. Interestingly, also ART-associated DMPs and DMRs were  
195 observed in its family member *NOTCH1*, which mediates uterine stromal differentiation and is  
196 essential for decidualization and implantation in mouse<sup>44</sup>.

197

198 When all the placentas were analyzed, moderate correlations were seen between *TRIM28* and  
199 *DLK1* as well as between *TRIM28* and *NOTCH3* expressions ( $r = 0.357^{***}$ ,  $n = 118$ , and  $r =$   
200  $0.358^{***}$ ,  $n = 118$ , respectively) (Supplementary Table 7). However, when the control and

201 ART placentas were analyzed separately, correlation between *TRIM28* and *NOTCH3* was only  
202 seen in the control ( $r = 0.472^*$ ,  $n = 39$ ) but not in the ART placentas. Interestingly, although  
203 there is no evidence of direct interaction between *DLK1* and *NOTCH3*, correlations between  
204 the expressions of the genes in all, control, ART, and SF placentas were observed ( $r =$   
205  $0.518^{***}$ ,  $n = 118$ ;  $r = 0.419^{**}$ ,  $n = 39$ ;  $r = 0.427^{**}$ ,  $n = 59$ ;  $r = 0.733^*$ ,  $n = 10$ , respectively).  
206

207 According to the GO:BP enrichment analysis, ART-associated gene expression is linked  
208 predominantly to vasculogenesis including endothelial cell development (*PECAMI*, *SIPR3*,  
209 *COL18A*, and *ROBO4*), renal vasculature development (*PECAMI*, *NOTCH3*, and *CD34*), and  
210 foam cell differentiation (*AGTRI*, *ABCA1*, and *CETP*) (FDR-corrected  $q$ -value  $< 0.05$ )  
211 (Fig. 1e, Supplementary Table 8). Interestingly, foam cells are a sign for vascular changes in  
212 the placenta, the so-called acute atherosclerosis, which has been observed frequently in non-  
213 transformed spiral arteries in pregnancies associated with pre-eclampsia, SGA, fetal death,  
214 spontaneous PTB, and preterm premature rupture of membranes<sup>45</sup>.  
215

### 216 **The separate effects of ART and subfertility**

217 To separate the effects of ART methods and subfertility, we compared gene expression of  
218 placentas derived from IUI and SF couples to controls ( $n = 10$ ,  $n = 10$ ,  $n = 39$ , respectively)  
219 (Supplementary Table 9). One DEG, upregulated *TSIX*, a non-coding RNA gene and an  
220 antisense to *X Inactive Specific Transcript (XIST)*, was observed in IUI and three  
221 downregulated DEGs (*ATG9B*, *SRRM2*, and *INSR*) in SF placentas. When both IUI and SF  
222 placentas were compared to controls, five downregulated DEGs (*DLK1*, *VIM*, *IGFBP5*, *TBX2*,  
223 and *TRPC6*) were detected. Notably, decreased counts of *DLK1* were also observed in SF  
224 placentas (Fig. 1d), suggesting that downregulation of *DLK1* associates with subfertility. By  
225 adding IUI and SF samples to the controls we were able to separate the potential effects of  
226 hormonal treatments and subfertility from the effects of *in vitro* culture of ART procedures.  
227 Interestingly, only 13 DEGs associated with *in vitro* culture (Fig. 1f, Supplementary Table 9).  
228

### 229 **ART-associated changes in IVF and ICSI placentas**

230 When IVF and ICSI placentas were compared separately to controls, 140 IVF-associated DMPs  
231 linking to 98 genes (Fig. 2a, Supplementary Table 10) and 439 DMRs linking to 417 genes  
232 were detected (Supplementary Table 11) ( $n = 50$ ,  $n = 30$ ,  $n = 77$ , respectively) (general  
233 characteristics in Supplementary Table 1). The ICSI placentas associated with 60 DMPs  
234 linking to 47 genes (Fig. 2b, Supplementary Table 12) as well as 63 DMRs linking to 48 genes

235 (Supplementary Table 13). Only five DMPs and one gene (*TCNI*) as well as 17 DMR-  
236 associated genes were common between the IVF and ICSI placentas and when the IVF  
237 placentas were compared to ICSI, none DMPs or DMRs were detected (Fig. 2c, Supplementary  
238 Table 14). Although the IVF-associated DMRs and the pathways in which they clustered were  
239 similar to ART result (Supplementary Table 15), this separate comparison revealed ICSI-  
240 associated DMRs which linked to genes *COLGALT1*, *DGKZ*, *PAX8*, *PAX8-ASI*, and *PDE4B*  
241 (Fig. 2c, Supplementary Table 14).

242

243 mRNA-seq analysis for the IVF ( $n = 38$ ) and control ( $n = 39$ ) placentas showed 14 DEGs (10  
244 down- and 4 upregulated), whereas a higher number, 46 genes (34 down- and 12 upregulated),  
245 was observed in the ICSI placentas ( $n = 21$ ) (Fig. 2d,f, Supplementary Tables 14 and 16). *DLKI*  
246 was the only common DEG between IVF and ICSI placentas. Interestingly, the upregulated  
247 genes *ZFY*, *RPS4Y1*, *PCDH11Y*, and *DDX3Y* in the ICSI placentas locate on chromosome Y  
248 and the expressions of them all correlated significantly with each other in ART male placentas,  
249 but not in the controls (Supplementary Table 7). Since male infertility was a common reason  
250 (44.4%) for the infertility among the analyzed ICSI male samples (Supplementary Table 17)  
251 the upregulated genes *DDX3Y*<sup>46</sup>, *ZFY*<sup>47</sup>, and *PCDH11Y*<sup>48</sup>, which all have been associated with  
252 male infertility in previous studies, are notable. Furthermore, the ICSI-associated DEGs  
253 *MAP1B*, *HBA1*, *EPHX1*, *HBB*, and *HBG2* enriched in response-to-toxic-substance pathway are  
254 also interesting (FDR-corrected  $q$ -value  $< 0.05$ ), considering that environmental exposures  
255 have been associated with male infertility in previous studies (Supplementary Table 18).  
256 Epoxide hydrolases, such as *EPHX1*, are involved in detoxifying and excreting the  
257 environmental chemicals which are associated with decreased semen quality and male  
258 infertility<sup>49</sup>.

259

### 260 **ART-associated changes in FRESH and FET placentas**

261 Nearly equal amount of DMPs associated with the FRESH and FET placentas when they were  
262 compared separately to the controls ( $n = 42$ ,  $n = 38$ ,  $n = 77$ , respectively): 99 FRESH-associated  
263 DMPs were annotated to 97 genes and 93 FET DMPs to 59 genes (Fig. 3a-c, Supplementary  
264 Tables 19–21). Furthermore, 253 FRESH- and 100 FET-associated DMRs were observed  
265 (FDR  $< 0.05$ ) (Fig. 3c, Supplementary Tables 21–23). GO enrichment analysis of FRESH  
266 DMRs revealed BPs involved in pathways such as cell adhesion via plasma membrane  
267 adhesion molecules (FDR  $< 0.05$ ) and regulation of cytoskeleton organization ( $P < 0.05$ ),  
268 whereas FET DMRs clustered to the regulation of astrocyte differentiation and ion

269 transmembrane transporter activity, as well as peptidyl-arginine ADP-ribosylation ( $P < 0.05$ )  
270 (Supplementary Tables 24 and 25, respectively). Interestingly, FRESH DMRs in KEGG  
271 enrichment analysis clustered in T2D and insulin resistance, which did not emerge in the  
272 analysis for FET DMRs.

273  
274 mRNA-seq analysis for the FRESH, FET, and control ( $n = 30$ ,  $n = 29$ ,  $n = 39$ , respectively)  
275 placentas showed 41 FRESH-associated DEGs (35 down- and six upregulated) and only six  
276 FET DEGs (five down- and one upregulated) (Fig 3d-f, Supplementary Tables 21 and 26).  
277 Downregulated *DLK1* came up from both FRESH and FET placentas, but *NOTCH3* and  
278 *TRIM28* were significantly downregulated only in FRESH placentas (Fig. 3d-f). The only  
279 upregulated FET-associated DEG was *dermatan sulfate epimerase (DSE)*, which  
280 overexpression has been observed in several cancers and which associates with active  
281 angiogenesis, invasion, and proliferation<sup>50</sup>.

282  
283 Finally, we compared FRESH and FET placentas derived only from the IVF procedure to the  
284 controls ( $n = 25$ ,  $n = 25$ ,  $n = 77$ , respectively). A total of 34 DMPs and 25 DMRs were  
285 associating with IVF-FRESH placentas, whereas 29 DMPs and 30 DMRs associated with IVF-  
286 FET (Fig. 3g,h, Supplementary Tables 27 and 28, respectively). In both FRESH and IVF-  
287 FRESH placentas, the most interesting DMPs located in the regulatory regions of *ZFP57 zinc*  
288 *finger protein (ZFP57)* (cg13773306) and *NLR family pyrin domain containing 5 (NLRP5)*  
289 (cg14217229), which have been associated with multilocus imprinting disturbance<sup>51</sup> (Fig. 3i).  
290 Interestingly, *ZFP57*, which also had a DMR in ART, IVF, FRESH, and IVF-FRESH  
291 placentas, is a cofactor of *TRIM28*, and they both are required for the germline imprinting<sup>52,53</sup>.  
292 The DNAm level of *ZFP57* DMP (cg13773306) correlated with *TRIM28* expression in ART,  
293 ICSI and FET placentas, ( $r = 0.33^*$ ,  $n = 59$ ;  $r = 0.6^{**}$ ,  $n = 21$ ;  $r = 0.41^*$ ,  $n = 38$ , respectively),  
294 with *DLK1* expression in FET placentas ( $r = 0.4^*$ ,  $n = 38$ ), and with *NOTCH3* expression in  
295 ICSI placentas ( $r = 0.53^*$ ,  $n = 30$ ), supporting associations between DNAm and expression of  
296 these genes (Supplementary Table 29). Furthermore, the DNAm level of *NLRP5* DMP  
297 (cg14217229) correlated with *NOTCH3* expression in ART, ICSI, and FRESH placentas ( $r =$   
298  $0.34^{**}$ ,  $n = 59$ ;  $r = 0.54^*$ ,  $n = 21$ ;  $r = 0.44^*$ ,  $n = 30$ , respectively). There were only one DEG  
299 in IVF-FRESH placentas, downregulated *CBX6* (log fold change = -0.97, FDR = 0.01), and no  
300 DEGs in the IVF-FET placentas were observed ( $n = 19$ ,  $n = 19$ ,  $n = 39$ , respectively).

301

302 **Sex-specific differences in ART-derived placentas**



303 To identify sex-specific effects of ART, we performed DNAm analyses including sex  
304 chromosomes for the placentas of male and female newborns separately. The GWAM overall  
305 level was higher in male placentas compared to females, which is consistent with a previous  
306 study<sup>29</sup> (Supplementary Fig. 3). A higher GWAM overall level was observed in ICSI male  
307 placentas compared to control males, and significantly higher compared to IVF males ( $n = 12$ ,  
308  $n = 42$ ,  $n = 24$ , respectively) ( $P = 0.04$ ). Furthermore, ICSI male placentas had significantly  
309 higher GWAM level at genomic locations 5'UTR and S\_Shore compared to control males as  
310 well as at 5'UTR, S\_Shelf and S\_Shore compared to IVF males ( $P = 0.03$ ,  $P = 0.03$ ,  $P < 0.05$ ,  
311  $P = 0.01$ ,  $P = 0.03$ , respectively). By contrast to the males, differences in GWAM overall level  
312 were not observed between control, IVF, and ICSI female placentas ( $n = 35$ ,  $n = 26$ ,  $n = 18$ ,  
313 respectively). However, the ICSI female placentas had significantly lower GWAM at S\_Shelf  
314 compared to IVF females ( $P = 0.007$ ).

315

316 Moreover, a trend of higher GWAM in both male and female FET placentas compared to  
317 FRESH and controls was observed (Supplementary Fig. 3). In FET male placentas the GWAM  
318 level was significantly higher at N\_Shelf compared to FRESH males, and in FET female  
319 placentas significantly lower at 1stExon compared to FRESH females ( $n = 22$ ,  $n = 14$ ,  $n = 16$ ,  
320  $n = 28$ , respectively) ( $P = 0.03$  and  $P = 0.04$ , respectively).

321

322 Sex-specific examination of Alu, LINE1, and EVR REs revealed significantly lower Alu  
323 DNAm in ICSI male placentas ( $n = 12$ ) compared to IVF males ( $n = 24$ ) (Supplementary Fig.  
324 4). Furthermore, ICSI female placentas ( $n = 18$ ) had significantly lower LINE1 DNAm level  
325 compared to control females ( $n = 35$ ) ( $P = 0.03$  and  $P = 0.04$ , respectively).

326

327 In ART male placentas, there were only one hypermethylated DMP compared to control males  
328 (ART:  $n = 36$ , control:  $n = 42$ ), whereas 20 DMPs and eight DMRs were observed in ART  
329 females (ART:  $n = 44$ , control:  $n = 35$ ) (Supplementary Table 30). Interestingly, mRNA-seq  
330 for male placentas (ART:  $n = 29$ , control:  $n = 19$ ) revealed 21 DEGs (18 down, 3 up) (FDR <  
331 0.05) clustering in pathways of endothelial and epithelial cell development in GO:BP  
332 enrichment analysis, and none DEGs in the ART females (ART:  $n = 30$ , control:  $n = 20$ )  
333 (Supplementary Table 31). In IVF male placentas five DEGs (downregulated *PECAMI*,  
334 *SPARCL1*, *DLK1*, and *SIPR3* and upregulated *LYPLAI*) were observed compared to control  
335 males, and in IVF female placentas 11 DMPs and four DMRs were observed compared to  
336 control females ( $n = 20$ ,  $n = 19$ ,  $n = 26$ ,  $n = 35$  respectively). Despite of the small sample size



337 in sex-specific analysis of ICSI samples, 16 DEGs were observed in ICSI male placentas (ICSI:  
338  $n = 9$ , control:  $n = 19$ ), including five upregulated genes, *DDX3Y*, *EIF1AY*, *ZFY*, *RPS4Y1*, and  
339 *PCDH11Y*, locating all on chromosome Y. In female placentas (ICSI:  $n = 12$ , control  $n = 20$ ),  
340 six DEGs were observed including downregulated *CASP2* and upregulated *TFPI2*, *CSH1*,  
341 *CGA*, *PSG2*, and *PSG3*.

342

343 When FRESH and FET placentas were analyzed sex-specifically, only one downregulated  
344 DEG (*SPARCL*), was observed in FRESH male placentas (FRESH:  $n = 11$ , control:  $n = 19$ )  
345 and 21 DMPs and 2 DMRs in the FRESH female placentas (FRESH:  $n = 28$ , control:  $n = 35$ )  
346 (Supplementary Table 30 and 31). In FET male placentas, one DMR (*HTT-AS 3* CpG) (FET:  
347  $n = 22$ , control:  $n = 42$ ), and 11 DEGs clustering in GO:BP pathway term protein refolding  
348 (*HSPA13*, *HSPA5*), were observed (FET:  $n = 18$ , control:  $n = 19$ ).

349

### 350 **Associations between placental gene expression and phenotypes**

351 Potential correlations between *TRIM28*, *NOTCH3*, and *DLK1*, and phenotypes of newborns  
352 and their mothers were calculated (Supplementary Table 29). When all samples were  
353 examined, there was a weak correlation between placental *NOTCH3* expression and birth  
354 weight (BW) (SD) ( $r = 0.272^{**}$ ,  $n = 118$ ), and it was driven by male samples in which the  
355 correlations between *NOTCH3* and BW as well as *NOTCH3* and birth length (BL) (SD) were  
356 observed ( $r = 0.414^{**}$ ,  $n = 58$ , and  $r = 0.369^{**}$ ,  $n = 58$ , respectively). Furthermore, *NOTCH3*  
357 expression correlated with the BW and BL (SD) of controls ( $r = 0.41^*$ ,  $n = 39$ , and  $r = 0.386^*$ ,  
358  $n = 39$ , respectively), with BW and BL (SD) and placental weight of ICSI ( $r = 0.441^*$ ,  $r =$   
359  $0.503^*$ , and  $r = 0.463^*$ ,  $n = 21$ , respectively), as well as with BW and BL (SD) of FET  
360 newborns ( $r = 0.419^{**}$ ,  $n = 29$ ;  $r = 0.441^*$ ,  $n = 29$ , respectively). The correlation between  
361 *NOTCH3* and BL among the ICSI samples was driven by male newborns.

362

363 In all male samples there was a negative correlation between *TRIM28* expression and maternal  
364 age ( $r = -0.339$ ,  $P = 0.009$ ,  $n = 58$ ) and in all the female samples *TRIM28* correlated weakly  
365 with GA ( $r = 0.257^*$ ,  $n = 60$ ). Furthermore, *TRIM28* expression correlated negatively with  
366 maternal weight gain during pregnancy in the control and ART placentas ( $r = -0.418^*$ ,  $n = 37$ ;  
367  $r = -0.295^*$ ,  $n = 54$ , respectively). In the ART placentas it was driven by ICSI, specifically by  
368 ICSI female placentas ( $r = -0.596^{**}$ ,  $n = 19$ ;  $r = -0.655^*$ ,  $n = 11$ , respectively). Also, placental

369 *TRIM28* expression correlated negatively with maternal weight gain and positively with  
370 maternal BMI in the FRESH placentas ( $r = -0.388^*$ ,  $n = 26$ ;  $r = 0.363^*$ ,  $n = 30$ , respectively).

371

372 Placental *DLK1* expression correlated with ART female BL (SD) ( $r = 0.394^*$ ,  $n = 30$ ) driven  
373 by ICSI females ( $r = 0.676^*$ ,  $n = 12$ ), and negatively with maternal weight gain during the  
374 pregnancy in IVF females ( $r = -0.618^*$ ,  $n = 15$ ).

375

### 376 **ART- and subfertility-associated placental imprinting**

377 Finally, we focused on genomic imprinting since imprinting disorders have been associated  
378 with ART in several previous studies<sup>54</sup>. Imprinted genes are a group of parent-of-origin  
379 monoallelically expressed genes, which are maintained by correctly methylated imprinting  
380 control regions (ICRs) established in the germline. A total of 19 ART- and/or ART subgroup-  
381 associated DMRs on the microarrays are annotated to the imprinted genes<sup>55</sup> of which 13 were  
382 hypomethylated (ART:  $n = 80$ , IVF:  $n = 50$ , ICSI:  $n = 30$ , FRESH:  $n = 42$ , FET:  $n = 38$ , control:  
383  $n = 77$ ) (Supplementary Table 32). Six of these (*BLCAP*, *KCNQ1*, *KCNQ1OT1*, *NNAT*, *PEG3*,  
384 and *ZIM2*) have been associated with ART also in previous EWASs<sup>12,16,21,56</sup> and were found to  
385 be hypomethylated as in the current study. To focus specifically on ICRs, we compared 826  
386 CpGs on ICRs compiled by Ochoa and colleagues<sup>57</sup> between ART and control placentas and  
387 observed significant differences in 115 sites (90 hypo- and 25 hypermethylated) ( $P < 0.05$ )  
388 (Supplementary Table 32). After multiple testing correction, 16 CpG sites remained significant  
389 (Bonferroni adjusted  $P < 0.05$ ). Furthermore, by using genome-wide DNAm data we examined  
390 if the ART-associated DNAm changes were particularly enriched in the ICRs. There were 15  
391 ART-associated CpGs (13 hypo- and 2 hypermethylated) locating in the ICRs ( $FDR < 0.05$ )  
392 and according to the hypergeometric distribution test, imprinted regions were significantly  
393 enriched with DNAm changes ( $P = 0.009$ ).

394

395 In the current study, we observed ART-associated hypomethylation in *ZFP57* as well as  
396 prominent downregulation of paternally expressed *DLK1*, which locates in a paternally  
397 imprinted *DLK1-DIO3* locus. Since *ZFP57* binds to and stabilizes paternally methylated ICR  
398 in *DLK1-DIO3* locus in mouse<sup>58</sup> and *TRIM28* is a cofactor of *ZFP57*<sup>52,53</sup>, we examined ICR  
399 DNAm at this locus of ART (IVF:  $n =$  four, ICSI:  $n =$  four), SF ( $n =$  four), and control ( $n =$  six)  
400 placentas by traditional bisulphite sequencing (Fig. 4a). The analyzed ICR sequence is next to  
401 the repeated sequence motifs, which contribute to the DNAm of the ICR<sup>58</sup>. Maternal and

402 paternal alleles were distinguished by two single nucleotide polymorphisms (SNPs)  
403 (rs1884539 and rs75998174) when possible. Interestingly, although we did not see highly  
404 methylated paternal and demethylated maternal allele in this specific ICR sequence, we  
405 observed significantly decreased total DNAm in the ICR of SF placentas compared to control  
406 (CpG1:  $P = 0.003$ , CpG2:  $P = 0.007$ ) and ART placentas (CpG1:  $P = 0.002$ , CpG7:  $P = 0.047$ )  
407 (Fig. 4b, Supplementary Fig. 5). However, we did not observe significantly decreased DNAm  
408 in the ART placentas compared to controls, which indicated that the ICR hypomethylation is  
409 not the only mechanism which affects the complex *DLKI* regulation<sup>59,60</sup>.

410

## 411 **DISCUSSION**

412

413 In this study, we performed the first genome-wide DNAm and gene expression analyses of  
414 human placentas from ART pregnancies as far as we are aware. Those pregnancies are not a  
415 homogeneous group, but differ from each other due to the ART procedures, causes of  
416 underlying infertility, and sex of the child. By combining the omics data to the phenotypic  
417 information and conducting method- and sex-specific analyses, it was possible to perceive the  
418 associations between molecular alterations and phenotypic features. There were only a few  
419 common ART procedure-associated alterations in the IVF and ICSI placentas, suggesting a  
420 strong impact of the underlying sub/infertility on the DNAm and gene expression rather than  
421 the effects of the *in vitro* culture. Furthermore, we confirmed previous findings about the  
422 procedure-specific effect of FET and observed heavier FET placentas compared to the FRESH  
423 placentas. Our observation about the lower amount of gene expression changes in the FET  
424 placentas compared to FRESH was consistent with this. Although freezing might be a  
425 challenging environmental insult for the embryo, it enables to avoid the hormonal disturbances  
426 caused by ovarian stimulation in FRESH. Nearly all (82%) of the FET pregnancies in our study  
427 have been started by natural cycle, which could explain the differences between FRESH and  
428 FET placentas.

429

430 In some studies, the more invasive ICSI procedure has been associated with a higher risk of  
431 birth defects<sup>61</sup>, which is concerning due to the increased use of this method. In the current  
432 study, more changes in gene expression were observed in the ICSI placentas compared to IVF.  
433 Male factor infertility was a prominent reason for ICSI in this study, which could explain the  
434 observed alterations. This can be seen in a small number of common ART-associated genes in

435 IVF and ICSI placentas as well as in many male infertility-associated genes on the Y  
436 chromosome in the ICSI male placentas. Indeed, in addition to information about the placenta  
437 itself, placenta could offer a “molecular window” to early development<sup>62-64</sup>, even to the germ  
438 cells. The origin of these early alterations and their potential to provide future biomarkers of  
439 infertility should be studied.

440

441 Furthermore, in addition to several sex-specific ART-associated alterations, we observed  
442 considerable differences between the ICSI males and females. The placental GWAM of ICSI  
443 females were more hypomethylated compared to ICSI males, and ICSI female newborns were  
444 smaller at birth – even significantly smaller HCs compared to controls were observed. Sex-  
445 specific differences in ICSI have been observed also in previous studies. A significantly higher  
446 number of trophoblast cells in ICSI male embryos was detected compared to their female  
447 counterparts, which was not observed when IVF male and female embryos were compared<sup>65</sup>.  
448 Also previously, ICSI female newborns had significantly smaller BWs (SD) as well as HCs  
449 (SD) at the ages of 18 and 36 months (the information about the HC at birth was lacking)  
450 compared to controls<sup>66</sup>. The number of sex-specific studies so far is surprisingly small and  
451 more studies with larger sample sizes are needed to verify this discovery as well as to find out  
452 whether this is caused by the ICSI method or by the underlying male infertility.

453

454 In addition to confirming previous ART-associated alterations observed in blood and placental  
455 samples, we found new candidate genes *DLK1*, *TRIM28*, and *NOTCH3* for ART-associated  
456 phenotypes. By performing cell type fragment analysis, we observed a significantly lower  
457 number of stromal cells in the ART placentas compared to controls. Interestingly, it has been  
458 suggested that differences in placental mesenchymal stromal cells could lead to impaired  
459 vascular development and consequently to restricted growth<sup>67,68</sup>. This is supported by our gene  
460 expression analysis, in which the most prominent ART-associated changes were linked to  
461 vasculogenesis, and where the downregulation of *NOTCH3* and *TRIM28*, both involved in the  
462 regulation of angiogenesis through the VEGFR-DLL4-NOTCH signaling circuit<sup>69</sup>, was  
463 observed. Furthermore, *NOTCH3* expression correlated with BW (SD) of control newborns,  
464 with BW (SD), BL (SD), and placental weight of ICSI male newborns, as well as BW (SD)  
465 and BL (SD) of FET newborns. Since *NOTCH3* and *TRIM28* are not significantly  
466 downregulated in placentas of FET newborns – whose size is near to the control newborns –  
467 the downregulation of *NOTCH3* could explain the higher risk of LWB and SGA associated  
468 with FRESH. Interestingly, among the control and FET groups the maternal hormonal function

469 is not affected: in most cases the embryo was transferred in a natural cycle without the  
470 hormonal disturbances caused by ovarian stimulation. The role of hormones brought forth also  
471 in the enrichment analysis, where ART-associated DMRs linked to terms such as growth  
472 hormone synthesis, secretion, and action, as well as GnRH secretion, and estrogen signaling  
473 pathway. Recently, it has been shown that *TRIM28* modulates estrogen receptor  $\alpha$  and  
474 progesterone receptor signaling, which regulate endometrial cell proliferation, decidualization,  
475 implantation, and fetal development<sup>40</sup>. Considering all these observations, the functional links  
476 between *NOTCH3*, *TRIM28*, and the ART-associated cardiovascular phenotype should be  
477 studied. Also, the separate effects of hormonal ovarian stimulation in ART protocols and  
478 subfertility-associated impaired hormonal function on early development need to be clarified  
479 in the future.

480

481 Along with *TRIM28* and *NOTCH3*, one of our most interesting discoveries in the ART  
482 placenta concerned the prominent downregulation of imprinted *DLK1* as well as the pathways  
483 of insulin signaling, insulin resistance, T1D and T2D, which came forth in the DNAm analyses.  
484 The developmentally essential *DLK1* is a part of evolutionary conserved Delta-Notch pathway,  
485 and it inhibits adipogenesis by controlling the cell fate of adipocyte progenitors<sup>70,71</sup>. According  
486 to animal studies, mice without paternally expressed *DLK1* exhibit growth retardation and  
487 obesity while *DLK1* overexpression generate decreased fat mass, diet-induced obesity  
488 resistance, and reduced insulin signalling<sup>72,73</sup>. In human, mutations in *DLK1* gene have been  
489 reported as a cause of central precocious puberty associated with obesity and metabolic  
490 syndrome with undetectable DLK1 serum levels<sup>74</sup>. Furthermore, in Temple syndrome, where  
491 *DLK1* expression is downregulated due to the maternal uniparental disomy of the imprinted  
492 *DLK1* locus, phenotypic features such as prenatal growth failure, short postnatal stature, female  
493 early onset puberty, and truncal obesity have been observed<sup>75</sup>. Since increased risks for SGA,  
494 rapid postnatal growth, and female early onset puberty<sup>6</sup> have all been associated with ART  
495 children, *DLK1* is a plausible candidate gene for the phenotypic effects associated with ART.

496

497 In addition to the downregulation of *DLK1* expression, we observed significant changes in  
498 *ZFP57*, *TRIM28*, and *NLRP5*, which all are needed for the stability of DNAm in the imprinted  
499 regions. We observed enrichment of decreased DNAm in several ICRs – common binding sites  
500 of *ZFP57* and *TRIM28* – suggesting that the machinery, which normally stabilizes the DNAm  
501 of ICRs globally could be impaired. This could explain the high variability in ART-associated  
502 imprinted genes observed in previous studies. Previously, mutations or dysregulation of *ZFP57*

503 have been associated with imprinting disorders such as transient neonatal diabetes mellitus<sup>76</sup>,  
504 which incidence has been shown to be higher among ART newborns<sup>77</sup>. Furthermore, mutations  
505 in *NLRP5* were responsible for early embryonic arrest in infertility patients<sup>78</sup>. More specific  
506 examination of *DLK1-DIO3* locus showed decreased DNAm of the ICR in SF placentas. This  
507 suggests that the instability of DNAm at this locus associates with subfertility, which is  
508 consistent with the decreased *DLK1* expression in the ART, SF, and IUI placentas observed in  
509 the current study, and with the previously reported associations between subfertility and  
510 decreased placental *DLK1* expression<sup>19</sup>. However, *TRIM28* can regulate the expression of  
511 imprinted *DLK1* in several ways<sup>59,60</sup> and therefore the interaction of these two genes should be  
512 examined by functional studies. Also, the effect of ageing on *TRIM28* expression and its  
513 associations with both *DLK1* and *NOTCH3* should be studied profoundly, due to the previous  
514 association between *TRIM28* and age-dependent infertility in mouse<sup>38</sup> as well as our observed  
515 negative correlation between placental *TRIM28* expression and maternal age.

516

517 These findings are also interesting in the perspective of fetal programming. According to the  
518 programming hypothesis, adverse conditions such as prenatal malnutrition in the critical  
519 developmental period may permanently program physiological processes. If there is plenty of  
520 food available postnatally, this programming may prove inappropriate and cause metabolic  
521 alterations leading to adult diseases such as obesity, T2D, metabolic syndrome, and  
522 cardiovascular disease<sup>79,80</sup>. Previously, Cleaton and colleagues showed in mouse that both *Dlk1*  
523 expression in maternal tissues and circulating DLK1 derived from the fetus are necessary for  
524 appropriate maternal metabolic adaptations to pregnancy by allowing the switch to fatty acid  
525 use when resources are limited during fasting<sup>81</sup>. Also, they reported that the circulating DLK1  
526 level predicts embryonic mass in mouse and lower DLK1 levels were strongly associated with  
527 high-resistance patterns of flow in the umbilical artery and slow abdominal circumference  
528 growth velocity in a human cohort. Furthermore, DLK1 level enables to differentiate healthy  
529 SGA from pathologically small infants. Our observation about the downregulated placental  
530 *DLK1* and *TRIM28* as well as their negative correlation with maternal weight gain during the  
531 pregnancy suggest that they did not effectively inhibit maternal adipogenesis, resulting in  
532 increased maternal weight and impaired maternal metabolic adaptations to the pregnancy. This  
533 negative correlation was seen particularly in our IVF and ICSI female as well as FRESH  
534 placentas, in the subgroups where the relatively smaller placentas and newborns were derived  
535 from. The switch to fatty acid use in maternal tissues during fasting could be impaired,  
536 potentially causing restricted fetal growth and a higher risk for adult disorders in the future.



537 However, in the ART-associated phenotype the increased risk for LBW, SGA, rapid postnatal  
538 growth, and metabolic disorders would be a consequence of downregulation of *DLK1* caused  
539 by subfertility associated disorder, not a consequence of poor maternal nutrition as in the  
540 example of fetal programming. Notable, significant associations between subfertility and LBW  
541 have been observed in previous studies<sup>82</sup>.

542

543 In summary, the observed molecular changes in genome-wide DNAm and gene expression in  
544 the ART placentas were relatively subtle, which is a finding in line with the fact that the  
545 majority of the ART conceived children are as healthy as newborns from natural conceptions.  
546 Decreased expression of *TRIM28*, *DLK1*, and *NOTCH3* as well as ART-associated DNAm in  
547 *ZFP57* and *NLRP5* bring forth potential mechanisms for the metabolic and phenotypic features  
548 including growth disturbance and imprinting disorders, which have been associated with ART.  
549 Considering that the observed changes associated also with subfertility, they offer a precious  
550 insight to the molecular background of infertility.

551

## 552 **METHODS**

553

### 554 **Epigenetics of ART (epiART) Cohort**

555 Finnish, Caucasian couples applied to fertilization treatment in the Fertility clinic of the Family  
556 Federation of Finland or the Reproductive Medicine Unit of Helsinki University Central  
557 Hospital, Finland were recruited to this study and the samples were collected during the years  
558 2015–2021. The epiART cohort includes 80 newborns fertilized using ART (IVF  $n = 50$  and  
559 ICSI  $n = 30$ ) of which 42 using FRESH and 38 using FET embryos. Moreover, the cohort  
560 includes newborns from pregnancies of couples who had went through IUI as well as from SF  
561 couples who were about to start or already started ART treatment but got pregnant  
562 spontaneously. More detailed information about the number of samples and newborns and  
563 maternal characteristics is presented in Table 1 and Supplementary Table 1. Parental infertility  
564 diagnoses of ART, IUI, and SF samples were categorized into male or female factor  
565 infertilities, infertility caused by multiple causes, and unexplained infertility (Supplementary  
566 Fig. 6 and Supplementary Table 17). Four cases in the ART group (5%) (IVF 4% and ICSI  
567 3.3%) and one in the IUI group (8.3%) used medication for chronic somatic disease  
568 hypothyroidism. Two ART cases (2.5%), both in IVF group (4%), had a psychiatric disorder  
569 diagnosis and the other one used medication for it (anxiety disorder). One in the IUI group  
570 (8.3%) had medication for a bipolar disorder. Pregnancy related disorders such as gestational

571 diabetes mellitus occurred in seven ART cases (8.8%) (IVF 12%, and ICSI 33.3%), two IUI  
572 (16.7%) and two SF (18.2%), hepatogestosis in three ART cases (3.8%) (IVF 4%, ICSI 3.3%)  
573 and pregnancy related hypertension in one IUI (8.3%) and one SF (9.1%). A total of 16 ART  
574 (20 %) (IVF 22% and ICSI 17%), four IUI (33%), and three SF (27%) deliveries were cesarean  
575 sections (CSs). The naturally conceived controls ( $n = 77$ ) were full term neonates born from  
576 uncomplicated pregnancies of healthy Finnish, Caucasian mothers collected during the years  
577 2013–2015 in Helsinki University Hospital, Finland. Five (6.5%) of the deliveries were CSs.

578

579 Differences in newborn birth measures and maternal characteristics between study groups were  
580 calculated, depending on the data distribution, by parametric two-tailed Student's *t*-test or  
581 nonparametric Mann-Whitney U test in the case of two groups, and by parametric One-Way  
582 ANOVA followed by Bonferroni post hoc or nonparametric Kruskal-Wallis test followed by  
583 pairwise comparisons in the case of multiple groups. Differences in BW, BL, and HC of the  
584 newborns were calculated using both anthropometric measures and the SDs of measures based  
585 on Finnish growth charts<sup>36</sup>, in which GA at birth, twinning, parity, and gender were considered  
586 when calculating the SDs (z-scores) of birth measures. SGA and LGA are characterized by  
587 weight and/or length at least 2 SD scores below or above the mean.

588

### 589 **Sample collection and preparation**

590 Placental samples of newborns were collected immediately after delivery. When this was not  
591 possible, the placenta was stored in the fridge for a maximum of 12 h and only DNA was  
592 extracted for further analyses. The placental biopsies (1 cm<sup>3</sup>) were collected from the fetal side  
593 of the placenta within a radius of 2–4 cm from the umbilical cord, rinsed in cold 1× PBS, fixed  
594 in RNAlater® (Thermo Fisher Scientific), and stored at –80 °C. Placental genomic DNA was  
595 extracted from one to four (3.5 on average) pieces of placental tissue samples using commercial  
596 QIAamp Fast DNA Tissue or AllPrep DNA/RNA/miRNA Universal Kits (Qiagen) or standard  
597 phenol-chloroform protocol. RNA was extracted from the same placental pieces as DNA (2.8  
598 pieces on average) by AllPrep DNA/RNA/miRNA Universal Kit. RNA quality was assessed  
599 using an Agilent 2100 Bioanalyzer (Agilent Technologies, Inc.), which was provided by the  
600 Biomedicum Functional Genomics Unit (FuGU) at the Helsinki Institute of Life Science and  
601 Biocenter Finland at the University of Helsinki.

602

### 603 **DNAm microarrays**

604 *DNAm measurements and data processing.* Genomic DNA (1000 ng) from available placental  
605 samples (sample information in Supplementary Table 1) was sodium bisulfite-converted using  
606 the Zymo EZ DNAm™ kit (Zymo Research), and genome-wide DNAm was assessed with  
607 Infinium Methylation EPIC BeadChip Kit (Illumina) following a standard protocol at the  
608 Institute for Molecular Medicine Finland. The raw DNAm dataset was pre-processed, quality  
609 controlled, and filtered using ChAMP R package<sup>83</sup> with default settings: the detection *P*-value  
610 cutoff was set at  $P = 0.01$ , and probe bead count  $> 3$  in at least 95% of samples. All probes and  
611 samples passed these quality control thresholds and were included in the subsequent steps.  
612 Type-I and Type-II probes were normalized using the *adjustedDasen* method<sup>84</sup> in *wateRmelon*  
613 R package<sup>85</sup>. Potential effects caused by technical factors and biological covariates were  
614 studied from singular value decomposition plots. The data was corrected for the effects of  
615 array, slide, batch, DNA extraction method, and placental type (stored in a fridge before  
616 sampling or not) by the Empirical Bayes method using the R package *ComBat*<sup>86</sup>. After *ComBat*  
617 adjustment, probes located in sex chromosomes and probes binding to polymorphic and off-  
618 target sites were filtered. Moreover, probes in Finnish-specific SNPs, which overlap with any  
619 known SNPs with global minor allele frequency were removed. Population-specific masking  
620 was obtained from Zhou et al.<sup>87</sup>.

621  
622 Subsequently, a total of 746,966 probes were retained for further downstream analysis. Probes  
623 in sex chromosomes (16,945 probes for males and 16,651 probes for females) were included  
624 in sex-specific analyses. Annotation information was merged to corresponding probes from  
625 *IlluminaHumanMethylationEPICanno.ilm10b4.hg19* R package<sup>88</sup>, which is based on the file  
626 “*MethylationEPIC\_v-1-0\_B4.csv*” from Illumina<sup>89</sup>. Probe genomic locations relative to gene  
627 and CpG island were annotated based on University of California, Santa Cruz (UCSC)  
628 database. If the location information was missing, probe was marked as “unknown.” In the case  
629 of multiple location entries, group “others” was used. Otherwise, the following abbreviations  
630 were used: TSS1500: 1500 bp upstream of transcription start site, TSS200: 200 bp upstream of  
631 TSS, UTR: untranslated region, N\_shelf: north shelf, N\_shore: north shore, S\_shore: south  
632 shore, S\_shelf: south shelf. Probes were annotated to genes based on, in addition to UCSC, also  
633 GENCODE Basic V12 and Comprehensive V12 databases.

634  
635 *DMP analysis.* Genome-wide differential DNAm analysis by using M values was performed  
636 by R package *Limma*<sup>90</sup>, and the linear model was adjusted to consider biological covariates  
637 newborn sex and maternal age and pre-pregnancy BMI. *Planet R* package<sup>91</sup> was used to count

638 placental cell-type fractions by CIBERSORT method with unfiltered data and used as an  
639 adjusting factor in the model.  $\beta$  values were used for visualization and interpretation of the  
640 results. DMPs were considered as significant when DNAm difference was greater than 5% ( $\Delta\beta$   
641  $\leq -0.05$  and  $\Delta\beta \geq 0.05$ ) and FDR-corrected  $P$ -value smaller than 0.05. Benjamini-Hochberg  
642 procedure was used to control for FDR. To calculate the differences in placental cell type  
643 composition between the study groups, depending on the data distribution, parametric or  
644 nonparametric two-tailed  $t$ -test in the case of two groups, and parametric One-Way ANOVA  
645 followed by Bonferroni *post hoc* or nonparametric Kruskal-Wallis test followed by Wilcoxon  
646 Rank Sum Exact test in the case of multiple groups were used.

647

648 *DMR and Pathway analysis.* DMRcate R package<sup>92</sup> was used to analyze DMRs. The method  
649 uses minimum description length for detecting region boundaries in DMR identification.  
650 DMRcate was adjusted to determine probes ( $\geq 3$ ) in a region with maximal allowed genomic  
651 distance of 1000 bp having FDR  $< 0.05$ . DMRs with Fisher's combined probability test  $P <$   
652  $0.05$  were considered significant. DMRs were annotated to imprinted genes based on  
653 Geneimprint database<sup>55</sup>. Pathway analysis was performed for significant DMRs by *goregion*  
654 function in missMethyl R package<sup>93</sup> and GO:BP and KEGG knowledgebases were used as a  
655 source. When the GO terms were not significant after FDR correction, the terms with the  
656 nominal  $P$ -value  $< 0.05$  were reported.

657

658 *GWAM analysis.*  $\beta$  values of all probes in the array (normalized, ComBat adjusted, and filtered  
659 data) were used to calculate placental GWAM<sup>94</sup> levels sample-wise. Differences between the  
660 study groups were calculated by parametric or nonparametric two-tailed  $t$ -test depending on  
661 the data distribution in the case of two groups. In the case of multiple groups, One-Way  
662 ANOVA followed by Tukey's honestly significant difference (HSD) test was used.

663

664 *RE DNAm analysis.* Processed DNAm data (M values) was used to predict DNAm in Alu,  
665 EVR, and LINE1 elements sample-wise using Random Forest-based algorithm implemented  
666 by REMP R package<sup>95</sup>. Less reliable predicted results were trimmed according to quality score  
667 threshold 1.7 and missing rate 0.2 (20%). Differences between the study groups were calculated  
668 by parametric or nonparametric two-tailed  $t$ -test depending on the data distribution in the case  
669 of two groups. In the case of multiple groups, One-Way ANOVA followed by Tukey's HSD  
670 test was used.

671

672 *ICR analysis.* Enrichment of ART-associated CpGs at ICRs was measured with  
673 hypergeometric distribution analysis. In total of 826 CpG sites located at ICRs<sup>57</sup> were identified  
674 in our genome-wide DNAm data, of which 15 CpGs were significantly differentially  
675 methylated (FDR < 0.05). Enrichment of these ICR-associated CpGs were compared to all  
676 CpGs in the EPIC array with *phyper* function in R. All CpGs at the ICRs were compared  
677 between ART and control placentas by two-tailed Student's *t*-test. Bonferroni adjustment was  
678 used for multiple comparison.

679

### 680 **Traditional bisulfite sequencing**

681 A total of eight ART (four IVF, four ICSI, two/sex), four SF (two/sex), and six control placental  
682 samples (three/sex) were subjected to bisulfite sequencing. Samples were chosen based on  
683 mRNA-seq counts, control samples having the highest and ART and SF samples the lowest  
684 counts. Paternal and maternal alleles were distinguished according to rs1884539(A/G) and  
685 rs75998174(A/G) polymorphisms at the *DLK1-DIO3* ICR. Primers were designed to  
686 incorporate the polymorphisms using Bisulfite Primer Seeker tool (Zymo Research)<sup>96</sup> (forward  
687 5'GGTTTATAGTTGTTTATGGTTTGTTAAT and reverse  
688 5'CTCCAACAAAAATTCCTTAACTAAATT). The 451 bp amplicon (chr14:101,277,375-  
689 101,277,826) covered 12 CpG sites at the ICR. Two separate bisulfite conversions were  
690 performed for 500 ng of genomic DNA using EZ DNA Methylation™ kit (Zymo Research)  
691 and pooled afterwards. To avoid possible PCR bias, three independent 20 µl PCR reactions  
692 (HotStar PCR kit, Qiagen) were performed per sample using annealing temperature 56 °C.  
693 PCR reactions were gel isolated, and the three reactions of each sample were pooled and  
694 purified using NucleoSpin Gel and PCR Clean-up Kit (Macherey-Nagel). The purified PCR  
695 fragments were ligated into pGEM®-T Easy Vector (Promega) and cloned by standard protocol.  
696 The recombinant-DNA clones were purified using NucleoSpin® Plasmid EasyPure kit  
697 (Macherey-Nagel) according to manufacturer's instructions. The sequences were analyzed by  
698 BIQ Analyzer<sup>97</sup> excluding the clones with lower than 90% conversion rate from the dataset. A  
699 total of eight to 30 clones of each individual were successfully sequenced (Supplementary Fig.  
700 5). DNAm differences in CpG sites between study groups (control, ART, SF) were calculated  
701 by One-Way ANOVA followed by Bonferroni post hoc.

702

### 703 **mRNA-seq analysis**

704 *Differential expression analysis.* Drop-seq pipeline<sup>98</sup> was used to construct the mRNA-seq  
705 count table for available placental RNA samples (sample information in Supplementary Table  
706 5) provided by FuGU. A total of 34,989 transcripts were identified for downstream analysis.  
707 Principal component analysis implemented in DESeq2<sup>99</sup> was used to identify batch effects, and  
708 ComBat-seq<sup>100</sup> was used to adjust separate mRNA-seq batches. Differential expression  
709 analysis was performed by DESeq2 R package, with model adjusting for newborn sex. Genes  
710 were considered as differentially expressed when FDR-corrected *P*-value was < 0.05.  
711 Benjamini-Hochberg procedure was used to control for FDR.

712

713 *Pathway analysis.* *enrichgo* function in R package clusterProfiler version 4.0<sup>101</sup> was used to  
714 perform gene-set enrichment analysis for significant DEGs. The GO knowledgebase was used  
715 as the source for identifying significantly enriched BP terms (FDR-corrected *q*-value < 0.05).  
716 Benjamini-Hochberg procedure was used to control for FDR.

717

### 718 **Correlation analysis**

719 The within sample gene expression correlations were calculated using ComBat-seq-adjusted  
720 and Transcripts Per Million-normalized mRNA-seq counts and the correlations between gene  
721 expression, *ZFP57* (cg13773306), *NLRP5* (cg14217229) DNAm, newborn phenotype, and  
722 maternal characteristics using ComBat-seq-adjusted and DESeq2-normalized mRNA-seq  
723 counts by Spearman rank correlation.

724

### 725 **Statistical analysis**

726 All statistical analyses were conducted in R versions 4.2.3 and 4.3.1<sup>102</sup>, IBM SPSS Statistics  
727 for Windows, version 29.0 (IBM Corp.), or GraphPad Prism 9 software (GraphPad Software,  
728 Inc.). All data are expressed as the mean with  $\pm$ SD for a normal distribution of variables.  
729 Statistical analyses were performed as described in the relevant method sections and in the  
730 figure legends.

731

### 732 **ABBREVIATIONS**

733

734 *ART*: Assisted reproductive technology

735 *BL*: Birth length

736 *BMI*: Body mass index

737 *BP*: Biological process



738 *BW*: Birth weight  
739 *CS*: Cesarean section  
740 *DEG*: Differentially expressed gene  
741 *DLK1*: Delta like non-canonical Notch ligand 1  
742 *DMP*: Differentially methylated position  
743 *DMR*: Differentially methylated region  
744 *DNAm*: DNA methylation  
745 *DSE*: Dermatan sulfate epimerase  
746 *EVR*: Endogenous retrovirus  
747 *EWAS*: Eepigenome-wide association study  
748 *FET*: Frozen embryo transfer  
749 *FRESH*: Fresh embryo transfer  
750 *FuGU*: Biomedicum Functional Genomics Unit  
751 *GA*: Gestational age  
752 *GO*: Gene ontology  
753 *GWAM*: Genome-wide average DNAm level  
754 *HC*: Head circumference  
755 *HSD*: Honestly significant difference  
756 *ICR*: Imprinting control region  
757 *ICSI*: Intracytoplasmic sperm injection  
758 *IUI*: Intrauterine insemination  
759 *IVF*: In vitro fertilization  
760 *LBW*: Low birth weight  
761 *LGA*: Large for gestational age  
762 *LINE1*: Long interspersed nuclear element  
763 *mRNA-seq*: 3'mRNA sequencing  
764 *N\_shelf*: north shelf  
765 *N\_shore*: north shore  
766 *NLRP5*: NLR family pyrin domain containing 5  
767 *NOTHC3*: Notch receptor 3  
768 *PTB*: Preterm birth  
769 *RE*: Repetitive element  
770 *S\_shore*: south shore  
771 *S\_shelf*: south shelf

772 *SF*: Subfertile  
773 *SGA*: Small for gestational age  
774 *SNP*: Single nucleotide polymorphism  
775 *T1D*: Type I diabetes mellitus  
776 *T2D*: Type II diabetes mellitus  
777 *TRIM28*: Tripartite motif-containing protein 28  
778 *TSS*: Transcription starting site  
779 *TSS200*: 200 bp upstream of TSS  
780 *TSS1500*: 1500 bp upstream of transcription start site  
781 *UCSC*: University of California, Santa Cruz  
782 *UTR*: Untranslated region  
783 *XIST*: X Inactive Specific Transcript  
784 *ZFP57*: ZFP57 zinc finger protein

785

#### 786 **Funding**

787 This project was supported by the Academy of Finland (332212) and University of Helsinki  
788 (Early Career Investigator Funding, Faculty of Medicine) (N.K-A.), Finnish Cultural  
789 Foundation (00190186, 00200185, 00212573, and 00222347) (P.A.), and Research funds from  
790 Helsinki University Hospital (A.T., T.T).

791

#### 792 **Contributions**

793 P.A., J.V., V.S-A., C.H-G., T.T., A.T. and N.K-A. contributed to the study design. H.K., V.S-  
794 A., and A.T. recruited the study participants. P.A., J.V., K.R., E.W., H.M., C.H. and N.K-A.  
795 contributed to the sample collection and processing. P.A., K.R., I.L. and N.K-A. contributed to  
796 the laboratory experiments. P.A., J.V., K.R., I.L. and N.K-A. contributed to the data analysis.  
797 P.A., J.V. and N.K-A. drafted the manuscript. All authors contributed to the revision of the  
798 manuscript. All authors gave final approval of the version to be published.

799

#### 800 **Supplementary material**

801 Supplementary Figures 1–6

802 Supplementary Tables 1–32

803

#### 804 **Ethics approval and consent to participate**

805 Informed consent was obtained from all participants and the study was approved by the Ethics  
806 Committee of Helsinki University Central Hospital (386/13/03/03/2012, 285/13/03/03/2013).

807

### 808 **Competing interests**

809 The authors declare no competing interests.

810

### 811 **Availability of data**

812 The datasets supporting the conclusions of the current study are included within the article and  
813 its additional files. Due to the sensitive nature of the patient data used, the data sets are not and  
814 cannot be made publicly available.

815

### 816 **Acknowledgements**

817 We gratefully thank all families that participated in this study. We would also like to  
818 acknowledge Teija Karkkulainen, Riikka Vass, and Ira Larsen for their contribution to the  
819 recruitment of the participants as well as Samuli Auvinen for his assistance with bisulphite  
820 sequencing visualization.

821

## 822 **REFERENCES**

823

- 824 1. European Ivf Monitoring Consortium, f.t.E.S.o.H.R. et al. ART in Europe, 2018: results  
825 generated from European registries by ESHRE. *Hum Reprod Open* **2022**, hoac022  
826 (2022).
- 827 2. Qin, J.B. et al. Worldwide prevalence of adverse pregnancy outcomes among singleton  
828 pregnancies after in vitro fertilization/intracytoplasmic sperm injection: a systematic  
829 review and meta-analysis. *Arch Gynecol Obstet* **295**, 285-301 (2017).
- 830 3. Vermey, B.G. et al. Are singleton pregnancies after assisted reproduction technology  
831 (ART) associated with a higher risk of placental anomalies compared with non-ART  
832 singleton pregnancies? A systematic review and meta-analysis. *BJOG* **126**, 209-218  
833 (2019).
- 834 4. Ceelen, M., van Weissenbruch, M.M., Vermeiden, J.P.W., van Leeuwen, F.E. & de  
835 Waal, H.A.D.V. Cardiometabolic differences in children born after in vitro fertilization:  
836 Follow-up study. *J Clin Endocr Metab* **93**, 1682-1688 (2008).

- 837 5. Guo, X.Y. et al. Cardiovascular and metabolic profiles of offspring conceived by  
838 assisted reproductive technologies: a systematic review and meta-analysis. *Fertility and*  
839 *Sterility* **107**, 622-631.e5. (2017).
- 840 6. Klemetti, R. et al. Puberty disorders among ART-conceived singletons: a Nordic  
841 register study from the CoNARTaS group. *Hum Reprod* **37**, 2402-2411 (2022).
- 842 7. Lazaraviciute, G., Kauser, M., Bhattacharya, S., Haggarty, P. & Bhattacharya, S. A  
843 systematic review and meta-analysis of DNA methylation levels and imprinting  
844 disorders in children conceived by IVF/ICSI compared with children conceived  
845 spontaneously. *Hum Reprod Update* **20**, 840-852 (2014).
- 846 8. Henningsen, A.A. et al. Imprinting disorders in children born after ART: a Nordic study  
847 from the CoNARTaS group. *Hum Reprod* **35**, 1178-1184 (2020).
- 848 9. Rönö, K. et al. The neurodevelopmental morbidity of children born after assisted  
849 reproductive technology: a Nordic register study from the Committee of Nordic  
850 Assisted Reproductive Technology and Safety group. *Fertility and Sterility* **117**, 1026-  
851 1037 (2022).
- 852 10. Maheshwari, A. et al. Is frozen embryo transfer better for mothers and babies? Can  
853 cumulative meta-analysis provide a definitive answer? *Human Reproduction Update*  
854 **24**, 35-58 (2018).
- 855 11. Melamed, N., Choufani, S., Wilkins-Haug, L.E., Koren, G. & Weksberg, R.  
856 Comparison of genome-wide and gene-specific DNA methylation between ART and  
857 naturally conceived pregnancies. *Epigenetics-U.S.* **10**, 474-483 (2015).
- 858 12. Estill, M.S. et al. Assisted reproductive technology alters deoxyribonucleic acid  
859 methylation profiles in bloodspots of newborn infants. *Fertility and Sterility* **106**, 629-  
860 639.e10. (2016).
- 861 13. El Hajj, N. et al. DNA methylation signatures in cord blood of ICSI children. *Hum*  
862 *Reprod* **32**, 1761-1769 (2017).
- 863 14. Novakovic, B. et al. Assisted reproductive technologies are associated with limited  
864 epigenetic variation at birth that largely resolves by adulthood. *Nat Commun* **10**, 3922  
865 (2019).
- 866 15. Tobi, E.W. et al. DNA methylation differences at birth after conception through ART.  
867 *Hum Reprod* **36**, 248-259 (2021).
- 868 16. Yeung, E.H. et al. Conception by fertility treatment and offspring deoxyribonucleic  
869 acid methylation. *Fertility and Sterility* **116**, 493-504 (2021).

- 870 17. Håberg, S.E. et al. DNA methylation in newborns conceived by assisted reproductive  
871 technology. *Nat Commun* **13**, 1896 (2022).
- 872 18. Rahimi, S. et al. Capturing sex-specific and hypofertility-linked effects of assisted  
873 reproductive technologies on the cord blood DNA methylome. *Clin Epigenetics* **15**, 82  
874 (2023).
- 875 19. Litzky, J.F. et al. Placental imprinting variation associated with assisted reproductive  
876 technologies and subfertility. *Epigenetics-Uk* **12**, 653-661 (2017).
- 877 20. Xu, N. et al. Comparison of Genome-Wide and Gene-Specific DNA Methylation  
878 Profiling in First-Trimester Chorionic Villi From Pregnancies Conceived With  
879 Infertility Treatments. *Reprod Sci* **24**, 996-1004 (2017).
- 880 21. Choufani, S. et al. Impact of assisted reproduction, infertility, sex and paternal factors  
881 on the placental DNA methylome. *Hum Mol Genet* **28**, 372-385 (2019).
- 882 22. Mani, S. et al. Embryo cryopreservation leads to sex-specific DNA methylation  
883 perturbations in both human and mouse placentas. *Hum Mol Genet* **31**, 3855-3872  
884 (2022).
- 885 23. Mann, M.R.W. et al. Selective loss of imprinting in the placenta following  
886 preimplantation development in culture. *Development* **131**, 3727-3735 (2004).
- 887 24. de Waal, E. et al. The cumulative effect of assisted reproduction procedures on  
888 placental development and epigenetic perturbations in a mouse model. *Hum Mol Genet*  
889 **24**, 6975-6985 (2015).
- 890 25. Rahimi, S. et al. Moderate maternal folic acid supplementation ameliorates adverse  
891 embryonic and epigenetic outcomes associated with assisted reproduction in a mouse  
892 model. *Hum Reprod* **34**, 851-862 (2019).
- 893 26. Ghosh, J., Coutifaris, C., Sapienza, C. & Mainigi, M. Global DNA methylation levels  
894 are altered by modifiable clinical manipulations in assisted reproductive technologies.  
895 *Clin Epigenetics* **9**, 14 (2017).
- 896 27. Choux, C. et al. The epigenetic control of transposable elements and imprinted genes  
897 in newborns is affected by the mode of conception: ART versus spontaneous  
898 conception without underlying infertility. *Hum Reprod* **33**, 331-340 (2018).
- 899 28. Barberet, J. et al. Do frozen embryo transfers modify the epigenetic control of imprinted  
900 genes and transposable elements in newborns compared with fresh embryo transfers  
901 and natural conceptions? *Fertility and Sterility* **116**, 1468-1480 (2021).
- 902 29. Gong, S. et al. Genome-wide oxidative bisulfite sequencing identifies sex-specific  
903 methylation differences in the human placenta. *Epigenetics-Uk* **13**, 228-239 (2018).

- 904 30. Andrews, S.V., Yang, I.J., Froehlich, K., Oskotsky, T. & Sirota, M. Large-scale  
905 placenta DNA methylation integrated analysis reveals fetal sex-specific differentially  
906 methylated CpG sites and regions. *Sci Rep-Uk* **12**, 9396 (2022).
- 907 31. Sandman, C.A., Glynn, L.M. & Davis, E.P. Is there a viability-vulnerability tradeoff?  
908 Sex differences in fetal programming. *J Psychosom Res* **75**, 327-335 (2013).
- 909 32. Tarrade, A., Panchenko, P., Junien, C. & Gabory, A. Placental contribution to  
910 nutritional programming of health and diseases: epigenetics and sexual dimorphism. *J*  
911 *Exp Biol* **218**, 50-58 (2015).
- 912 33. Kaartinen, N.M. et al. Male gender explains increased birthweight in children born after  
913 transfer of blastocysts. *Hum Reprod* **30**, 2312-2320 (2015).
- 914 34. Litzky, J.F. et al. Effect of frozen/thawed embryo transfer on birthweight, macrosomia,  
915 and low birthweight rates in US singleton infants. *Am J Obstet Gynecol* **218**, 433.e1-  
916 433.e10. (2018).
- 917 35. Coetzee, K., Ozgur, K., Bulut, H., Berkkanoglu, M. & Humaidan, P. Large-for-  
918 gestational age is male-gender dependent in artificial frozen embryo transfers cycles: a  
919 cohort study of 1295 singleton live births. *Reprod Biomed Online* **40**, 134-141 (2020).
- 920 36. Sankilampi, U., Hannila, M.L., Saari, A., Gissler, M. & Dunkel, L. New population-  
921 based references for birth weight, length, and head circumference in singletons and  
922 twins from 23 to 43 gestation weeks. *Ann Med* **45**, 446-454 (2013).
- 923 37. Gomes, L.G. et al. DLK1 Is a Novel Link Between Reproduction and Metabolism. *J*  
924 *Clin Endocr Metab* **104**, 2112-2120 (2019).
- 925 38. Tan, J.H.L., Wollmann, H., van Pelt, A.M.M., Kaldis, P. & Messerschmidt, D.M.  
926 Infertility-Causing Haploinsufficiency Reveals TRIM28/KAP1 Requirement in  
927 Spermatogonia. *Stem Cell Rep* **14**, 818-827 (2020).
- 928 39. Dalgaard, K. et al. Trim28 Haploinsufficiency Triggers Bi-stable Epigenetic Obesity.  
929 *Cell* **164**, 353-364 (2016).
- 930 40. Li, R. et al. TRIM28 modulates nuclear receptor signaling to regulate uterine function.  
931 *Nat Commun* **14**, 4605 (2023).
- 932 41. Bond, S.T. et al. Deletion of Trim28 in committed adipocytes promotes obesity but  
933 preserves glucose tolerance. *Nat Commun* **12**, 74 (2021).
- 934 42. Domenga, V. et al. Notch3 is required for arterial identity and maturation of vascular  
935 smooth muscle cells. *Gene Dev* **18**, 2730-2735 (2004).



- 936 43. Dietrich, B.V., K; Lackner, A. I.; Meinhardt, G; Koo, B-K.; Pollheimer, J.; Haider, S;  
937 Knöfler, M. NOTCH3 signalling controls human trophoblast stem cell expansion and  
938 differentiation. *bioRxiv* **2023.07.03.547490**(2023).
- 939 44. Afshar, Y. et al. Notch1 mediates uterine stromal differentiation and is critical for  
940 complete decidualization in the mouse. *Faseb J* **26**, 282-294 (2012).
- 941 45. Kim, J.Y. & Kim, Y.M. Acute Atherosclerosis of the Uterine Spiral Arteries:  
942 Clinicopathologic Implications. *J Pathol Transl Med* **49**, 462-471 (2015).
- 943 46. Dicke, A.K. et al. DDX3Y is likely the key spermatogenic factor in the AZFa region  
944 that contributes to human non-obstructive azoospermia. *Commun Biol* **6**, 350 (2023).
- 945 47. Holmlund, H., Yamauchi, Y., Ruthig, V.A., Cocquet, J. & Ward, M.A. Return of the  
946 forgotten hero: the role of Y chromosome-encoded Zfy in male reproduction. *Mol Hum*  
947 *Reprod* **29**, gaad025 (2023).
- 948 48. Anilkumar, T.R. et al. Expression of protocadherin 11Yb (PCDH11Yb) in seminal  
949 germ cells is correlated with fertility status in men. *Reprod Fert Develop* **29**, 2100-2111  
950 (2017).
- 951 49. Qin, Y.F. et al. Genetic variants in epoxide hydrolases modify the risk of  
952 oligozoospermia and asthenospermia in Han-Chinese population. *Gene* **510**, 171-174  
953 (2012).
- 954 50. Thelin, M.A. et al. Biological functions of iduronic acid in chondroitin/dermatan  
955 sulfate. *Febs J* **280**, 2431-2446 (2013).
- 956 51. Eggermann, T. et al. Trans-acting genetic variants causing multilocus imprinting  
957 disturbance (MLID): common mechanisms and consequences. *Clin Epigenetics* **14**, 41  
958 (2022).
- 959 52. Li, X.J. et al. A Maternal-Zygotic Effect Gene, Zfp57, Maintains Both Maternal and  
960 Paternal Imprints. *Dev Cell* **15**, 547-557 (2008).
- 961 53. Quenneville, S. et al. In Embryonic Stem Cells, ZFP57/KAP1 Recognize a Methylated  
962 Hexanucleotide to Affect Chromatin and DNA Methylation of Imprinting Control  
963 Regions. *Mol Cell* **44**, 361-372 (2011).
- 964 54. Cortessis, V.K. et al. Comprehensive meta-analysis reveals association between  
965 multiple imprinting disorders and conception by assisted reproductive technology. *J*  
966 *Assist Reprod Gen* **35**, 943-952 (2018).
- 967 55. Jirtle, R.L. Geneimprint. Imprinted Genes: by Species.  
968 <https://www.geneimprint.com/site/genes-by-species>. (2023).

- 969 56. Barberet, J. et al. DNA methylation profiles after ART during human lifespan: a  
970 systematic review and meta-analysis. *Human Reproduction Update* **28**, 629-655  
971 (2022).
- 972 57. Ochoa, E. et al. ImprintSeq, a novel tool to interrogate DNA methylation at human  
973 imprinted regions and diagnose multilocus imprinting disturbance. *Genet Med* **24**, 463-  
974 474 (2022).
- 975 58. Hara, S., Terao, M., Tsuji-Hosokawa, A., Ogawa, Y. & Takada, S. Humanization of a  
976 tandem repeat in IG-DMR causes stochastic restoration of paternal imprinting at mouse  
977 Dlk1-Dio3 domain. *Hum Mol Genet* **30**, 564-574 (2021).
- 978 59. Alexander, K.A., Wang, X., Shibata, M., Clark, A.G. & Garcia-Garcia, M.J. TRIM28  
979 Controls Genomic Imprinting through Distinct Mechanisms during and after Early  
980 Genome-wide Reprogramming. *Cell Rep* **13**, 1194-1205 (2015).
- 981 60. Lu, H.P. et al. TRIM28 Regulates Dlk1 Expression in Adipogenesis. *Int J Mol Sci* **21**,  
982 7245 (2020).
- 983 61. Davies, M.J. et al. Reproductive Technologies and the Risk of Birth Defects. *New Engl*  
984 *J Med* **366**, 1803-1813 (2012).
- 985 62. Auvinen, P. et al. Chromatin modifier developmental pluripotency associated factor 4  
986 (DPPA4) is a candidate gene for alcohol-induced developmental disorders. *Bmc Med*  
987 **20**, 495 (2022).
- 988 63. Laufer, B.I. et al. Placenta and fetal brain share a neurodevelopmental disorder DNA  
989 methylation profile in a mouse model of prenatal PCB exposure. *Cell Rep* **38**, 110442  
990 (2022).
- 991 64. Zhu, Y.H. et al. Placental methylome reveals a 22q13.33 brain regulatory gene locus  
992 associated with autism. *Genome Biol* **23**, 46 (2022).
- 993 65. Dumoulin, J.C. et al. Growth rate of human preimplantation embryos is sex dependent  
994 after ICSI but not after IVF. *Hum Reprod* **20**, 484-91 (2005).
- 995 66. Kai, C.M. et al. Serum insulin-like growth factor-I (IGF-I) and growth in children born  
996 after assisted reproduction. *J Clin Endocr Metab* **91**, 4352-4360 (2006).
- 997 67. Umaphathy, A. et al. Mesenchymal Stem/Stromal Cells from the Placentae of Growth  
998 Restricted Pregnancies Are Poor Stimulators of Angiogenesis. *Stem Cell Rev Rep* **16**,  
999 557-568 (2020).
- 1000 68. Boss, A.L., Chamley, L.W., Brooks, A.E.S. & James, J.L. Differences in human  
1001 placental mesenchymal stromal cells may impair vascular function in FGR.  
1002 *Reproduction* **162**, 319-330 (2021).

- 1003 69. Wang, Y.F. et al. TRIM28 regulates sprouting angiogenesis through VEGFR-DLL4-  
1004 Notch signaling circuit. *Faseb J* **34**, 14710-14724 (2020).
- 1005 70. Mitterberger, M.C. et al. DLK1(PREF1) is a negative regulator of adipogenesis in  
1006 CD105(+)/CD90(+)/CD34(+)/CD31(-)/FABP4(-) adipose-derived stromal cells from  
1007 subcutaneous abdominal fat pats of adult women. *Stem Cell Res* **9**, 35-48 (2012).
- 1008 71. Vietor, I. et al. The negative adipogenesis regulator Dlk1 is transcriptionally regulated  
1009 by Ifrd1 (TIS7) and translationally by its orthologue Ifrd2 (SKMc15). *Elife* **12**, e88350  
1010 (2023).
- 1011 72. Moon, Y.S. et al. Mice lacking paternally expressed Pref-1/Dlk1 display growth  
1012 retardation and accelerated adiposity. *Mol Cell Biol* **22**, 5585-5592 (2002).
- 1013 73. Villena, J.A. et al. Resistance to High-Fat Diet-Induced Obesity but Exacerbated  
1014 Insulin Resistance in Mice Overexpressing Preadipocyte Factor-1 (Pref-1) A New  
1015 Model of Partial Lipodystrophy. *Diabetes* **57**, 3258-3266 (2008).
- 1016 74. Dauber, A. et al. Paternally Inherited DLK1 Deletion Associated With Familial Central  
1017 Precocious Puberty. *J Clin Endocr Metab* **102**, 1557-1567 (2017).
- 1018 75. Ioannides, Y., Lokulo-Sodipe, K., Mackay, D.J.G., Davies, J.H. & Temple, I.K. Temple  
1019 syndrome: improving the recognition of an underdiagnosed chromosome 14 imprinting  
1020 disorder: an analysis of 51 published cases. *J Med Genet* **51**, 495-501 (2014).
- 1021 76. Mackay, D.J.G. et al. Hypomethylation of multiple imprinted loci in individuals with  
1022 transient neonatal diabetes is associated with mutations in ZFP57. *Nat Genet* **40**, 949-  
1023 951 (2008).
- 1024 77. Fauque, P. et al. Reproductive technologies, female infertility, and the risk of  
1025 imprinting-related disorders. *Clin Epigenetics* **12**, 191 (2020).
- 1026 78. Mu, J. et al. Mutations in NLRP2 and NLRP5 cause female infertility characterised by  
1027 early embryonic arrest. *J Med Genet* **56**, 471-480 (2019).
- 1028 79. Barker, D.J., Winter, P.D., Osmond, C., Margetts, B. & Simmonds, S.J. Weight in  
1029 infancy and death from ischaemic heart disease. *Lancet* **2**, 577-580 (1989).
- 1030 80. Barker, D.J.P. The developmental origins of chronic adult disease. *Acta Paediatr* **93**,  
1031 26-33 (2004).
- 1032 81. Cleaton, M.A.M. et al. Fetus-derived DLK1 is required for maternal metabolic  
1033 adaptations to pregnancy and is associated with fetal growth restriction. *Nat Genet* **48**,  
1034 1473-1480 (2016).


- 1035 82. Declercq, E. et al. Perinatal outcomes associated with assisted reproductive technology:  
1036 the Massachusetts Outcomes Study of Assisted Reproductive Technologies  
1037 (MOSART). *Fertil Steril* **103**, 888-895 (2015).
- 1038 83. Tian, Y. et al. ChAMP: updated methylation analysis pipeline for Illumina BeadChips.  
1039 *Bioinformatics* **33**, 3982-3984 (2017).
- 1040 84. Wang, Y.C. et al. InterpolatedXY: a two-step strategy to normalize DNA methylation  
1041 microarray data avoiding sex bias. *Bioinformatics* **38**, 3950-3957 (2022).
- 1042 85. Pidsley, R. et al. A data-driven approach to preprocessing Illumina 450K methylation  
1043 array data. *Bmc Genomics* **14**, 293 (2013).
- 1044 86. Johnson, W.E., Li, C. & Rabinovic, A. Adjusting batch effects in microarray expression  
1045 data using empirical Bayes methods. *Biostatistics* **8**, 118-127 (2007).
- 1046 87. Zhou, W.D., Laird, P.W. & Shen, H. Comprehensive characterization, annotation and  
1047 innovative use of Infinium DNA methylation BeadChip probes. *Nucleic Acids Res* **45**,  
1048 e22 (2017).
- 1049 88. Hansen, K. IlluminaHumanMethylationEPICanno.ilm10b4.hg19: Annotation for  
1050 Illumina's EPIC methylation arrays. R package version 0.6.0. (2017).
- 1051 89. Illumina. <https://www.illumina.com>. (2023).
- 1052 90. Ritchie, M.E. et al. limma powers differential expression analyses for RNA-sequencing  
1053 and microarray studies. *Nucleic Acids Res* **43**, e47 (2015).
- 1054 91. Yuan, V. et al. Cell-specific characterization of the placental methylome. *Bmc*  
1055 *Genomics* **22**, 6 (2021).
- 1056 92. Kolde, R., Martens, K., Lokk, K., Laur, S. & Vilo, J. seqlm: an MDL based method for  
1057 identifying differentially methylated regions in high density methylation array data.  
1058 *Bioinformatics* **32**, 2604-2610 (2016).
- 1059 93. Phipson, B., Maksimovic, J. & Oshlack, A. missMethyl: an R package for analyzing  
1060 data from Illumina's HumanMethylation450 platform. *Bioinformatics* **32**, 286-288  
1061 (2016).
- 1062 94. Li, S. et al. Genome-wide average DNA methylation is determined in utero. *Int J*  
1063 *Epidemiol* **47**, 908-916 (2018).
- 1064 95. Zheng, Y.A. et al. Prediction of genome-wide DNA methylation in repetitive elements.  
1065 *Nucleic Acids Res* **45**, 8697-8711 (2017).
- 1066 96. Zymo Research. Bisulfite Primer Seeker. [https://zymoresearch.eu/pages/bisulfite-](https://zymoresearch.eu/pages/bisulfite-primer-seeker)  
1067 [primer-seeker](https://zymoresearch.eu/pages/bisulfite-primer-seeker). (2023).

- 1068 97. Bock, C. et al. BiQ analyzer: visualization and quality control for DNA methylation  
1069 data from bisulfite sequencing. *Bioinformatics* **21**, 4067-4068 (2005).
- 1070 98. Macosko, E.Z. et al. Highly Parallel Genome-wide Expression Profiling of Individual  
1071 Cells Using Nanoliter Droplets. *Cell* **161**, 1202-1214 (2015).
- 1072 99. Love, M.I., Huber, W. & Anders, S. Moderated estimation of fold change and  
1073 dispersion for RNA-seq data with DESeq2. *Genome Biol* **15**, 550 (2014).
- 1074 100. Zhang, Y.Q., Parmigiani, G. & Johnson, W.E. ComBat-seq: batch effect adjustment for  
1075 RNA-seq count data. *Nar Genom Bioinform* **2**, lqaa078 (2020).
- 1076 101. Wu, T.Z. et al. clusterProfiler 4.0: A universal enrichment tool for interpreting omics  
1077 data. *Innovation-Amsterdam* **2**, 100141 (2021).
- 1078 102. Team, R.C. R: a language and environment for statistical computing. Vienna: R  
1079 Foundation for Statistical Computing. (2023).
- 1080

**Table 1. Samples sizes of each study group in phenotype, genome-wide DNAm and mRNA-seq analyses.** Study groups are presented in bold with sample sizes in each analysis including the number of samples in the sex-specific analyses. The ART subgroups are shown on a white background. The subgroups or sex-specific samples which are not included in the analyses are written in light gray. IUI and SF groups (indicated with asterisks) are not included in genome-wide DNAm analysis. ART: assisted reproductive technology, IVF: *in vitro* fertilization, ICSI: intracytoplasmic sperm injection, FRESH: fresh embryo transfer, FET: frozen embryo transfer, IUI: insemination, and SF: subfertile.


Group	Phenotypes and Genome-wide DNAm	Genome-wide mRNA-seq
	N (male/female)	N (male/female)
<b>Control</b>	77 (42/35)	39 (19/20)
<b>ART</b>	80 (36/44)	59 (29/30)
IVF	50 (24/26)	38 (20/18)
IVF-FRESH	25 (10/15)	19 (8/11)
IVF-FET	25 (14/11)	19 (12/7)
ICSI	30 (12/18)	21 (9/12)
ICSI-FRESH	17 (4/13)	11 (3/8)
ICSI-FET	13 (8/5)	10 (6/4)
FRESH	42 (14/28)	30 (11/19)
FET	38 (22/16)	29 (18/11)
<b>IUI</b>	12* (8/4)	10 (6/4)
<b>SF</b>	11* (5/6)	10 (4/6)






**Fig. 1. ART-associated differential DNAm and ART-, IUI-, SF-, and *in vitro* culture-associated differential gene expression.** **a** Volcano plot showing the distribution of associations between CpG sites and ART. DMPs with  $\Delta\beta \leq -0.065$  and  $\Delta\beta \geq 0.065$  are labeled based on UCSC RefGene Name for visualization. **b** Significantly enriched terms identified in KEGG enrichment analysis for DMRs ( $P < 0.05$ ). The 30 most significant pathways are shown. **c** Volcano plot showing the distribution of associations between mRNA expression and ART. The 28 most significant DEGs are labeled for visualization including only confirmed genes. **d** Normalized mRNA-seq counts of *TRIM28*, *DLK1*, and *NOTCH3* genes in control, ART, IVF, ICSI, FRESH, FET, IUI, and SF placental samples. Data

presented as mean  $\pm$ SD. \*FDR < 0.05 in genome-wide mRNA-seq analysis compared to controls. **e** Significantly enriched terms identified in GO:BP enrichment analysis for ART-associated DEGs (FDR-corrected  $q$ -value < 0.05). All significant pathways are shown. **f** Volcano plot showing the distribution of associations between mRNA expression and *in vitro* culture. All significant DEGs are labeled for visualization including only confirmed genes. In volcano plots, horizontal line marks FDR 0.05 and vertical line marks effect size  $\pm$ 0.05. Control  $n = 77$  and ART  $n = 80$  in DNAm and control  $n = 39$ , ART  $n = 59$ , IVF  $n = 38$ , ICSI  $n = 21$ , IUI  $n = 10$ , and SF  $n = 10$  in mRNA-seq analyses.



**Fig. 2. IVF- and ICSI-associated differential DNAm and gene expression.** **a** Volcano plot showing the distribution of associations between CpG sites and IVF. DMPs with  $\Delta\beta \leq -0.065$  and  $\Delta\beta \geq 0.065$  are labeled based on UCSC RefGene Name for visualization. **b** Volcano plot showing the distribution of associations between CpG sites and ICSI. DMPs with  $\Delta\beta \leq -0.055$  and  $\Delta\beta \geq 0.055$  are labeled based on UCSC RefGene Name for visualization. **c** Venn diagram showing the number of ART-associated DMPs as well as DMR-associated genes, which are in common between IVF and ICSI

placentas. **d** Volcano plot showing the distribution of associations between mRNA expression and IVF. All significant DEGs are labeled for visualization including only confirmed genes. **e** Volcano plot showing the distribution of associations between mRNA expression and ICSI. The 28 most significant DEGs are labeled for visualization. **f** Venn diagram showing the number of ART-associated DEGs, which are in common between IVF and ICSI placentas. In volcano plots, horizontal line marks FDR 0.05 and vertical line marks effect size  $\pm 0.05$ . Control  $n = 77$ , IVF  $n = 50$ , and ICSI  $n = 30$  in DNAm and control  $n = 39$ , IVF  $n = 38$ , and ICSI  $n = 21$  in mRNA-seq analyses.



**Fig. 3. FRESH- and FET-associated differential DNAm and gene expression.** **a** Volcano plot showing the distribution of associations between CpG sites and FRESH. DMPs with  $\Delta\beta \leq -0.057$  and  $\Delta\beta \geq 0.057$  are labeled based on UCSC RefGene Name for visualization. **b** Volcano plot showing the distribution of associations between CpG sites and FET. DMPs with  $\Delta\beta \leq -0.058$  and  $\Delta\beta \geq 0.058$  are labeled based on UCSC RefGene Name for visualization. **c** Venn diagram showing the number of ART-associated DMPs as well as DMR-associated genes, which are in common between FRESH and



**Fig. 4. ART- and SF-associated DNAm profiles at *DLK1-DIO3* ICR.** **a** Schematic figure about *DLK1* and *DLK1-DIO3* ICR. The chromosomal region chr14:101,277,232-101,277,826 at the ICR, containing repeated sequence with nine underlined motifs (chr14:101,277,232-101,277,411) and PCR amplified sequence (chr14:101,277,375-101,277,826), is presented. Primers spanning the amplicon are highlighted in gray and the covered 12 CpG sites and the SNPs (rs1884539A/G and rs75998174A/G) used to distinguish paternal and maternal alleles are bolded. **b** DNAm levels at 12 CpG sites in *DLK1-DIO3* ICR in control ( $n = 6$ ), ART ( $n = 8$ ), IVF ( $n = 4$ ), ICSI ( $n = 4$ ), and SF ( $n = 4$ ) placentas. Differences in DNAm at the CpG sites were calculated between control, ART, and SF placentas. Data presented as mean  $\pm$ SD. \* $P < 0.05$  and \*\* $P < 0.01$ , One-Way ANOVA followed by Bonferroni post hoc.